Open Access Research
Ongoing Clinical Trials led by Dr. Hill
To be screened for participation, please call (617) 855 2359.
Nabilone as a Medication for Marijuana Addiction (Participants may earn up to $955)
We are conducting this clinical trial at McLean Hospital to develop a medication to treat marijuana addiction. Nabilone is a medication similar to marijuana that is FDA-approved for nausea and vomiting associated with cancer chemotherapy. We aim to determine if treatment with nabilone will lessen the physical withdrawal symptoms (such as anxiety, irritability, and difficulty sleeping) that near-daily marijuana users who try to stop using abruptly can experience. In a randomized, double-blind, placebo-controlled trial, 60 cannabis-dependent participants ages 18-45 will receive medical management (MM) over a 10-week period, with half receiving nabilone treatment and half receiving placebo. Participants will also receive neuropsychological testing and 3 MRI scans during the trial to further study how nabilone may work.
Combination of Dronabinol and Clonidine for Marijuana Addiction in Patients with Mental Illness (Participants may earn up to $740)
In the second trial at McLean Hospital to develop a combination of medications to treat marijuana addiction, we are conducting a Stage 1 pilot feasibility study in participants with marijuana addiction and Axis I psychiatric disorders. Dronabinol is a medication in pill form that contains THC, the active ingredient in marijuana, and dronabinol is FDA-approved for nausea and vomiting associated with cancer chemotherapy. Clonidine is a medication that treats high blood pressure. In a randomized, double-blind, placebo-controlled trial, 18 cannabis-dependent male and female participants ages 18-45 with mental illness will receive medical management (MM) over a 10-week period, with half receiving treatment with the combination of dronabinol and clonidine and half receiving placebo.
D-cycloserine plus Nicotine Replacement Therapy and Cognitive Behavioral Therapy for Cigarette Smoking Cessation. (Participants may earn up to $510)
D-cycloserine is FDA-approved as a treatment for tuberculosis. It has been shown to affect how we process cues that induce fear and some researchers have wondered if D-cycloserine may enhance learning. In this trial, smokers ages 18-65 will receive D-cycloserine or placebo in addition to the nicotine patch and talk therapy for 10 weeks in an effort to stop smoking.
Please call (617)855-2359 for a telephone screen to determine eligibility for either study.